Dr. Anilkumar Thaghalli Shivanna is a Principal Scientist and Operations Lead at MatchCure Inc., Taiwan. He received his Ph.D. in Chemical and Materials Engineering from Chang Gung University, Taiwan, following postgraduate training in materials science. He subsequently conducted postdoctoral and translational research at Chang Gung Memorial Hospital and the Ivy Brain Tumor Center, Barrow Neurological Institute, USA. His research spans cancer nanomedicine, nanoparticle and liposomal drug delivery, tumor-targeted therapeutics, pharmacokinetics and biodistribution, translational oncology, patient-derived and multicellular 3D tumor models, high-throughput drug screening, and functional precision oncology. His work has focused on the development and preclinical evaluation of nanoparticle-based therapeutics, advanced tumor models, and scalable functional drug-screening strategies for cancer. His academic and professional recognitions include the Exceptional Reviewer 2026 recognition from Pharmaceutics (MDPI), a Ph.D. Fellowship from Chang Gung University, and Distinguished Alumni awards from Jain University, India.